Clinical Trial Update: Trial of Vemurafenib and Cobimetinib in Patients With Advanced BRAFV600 Mutant Melanoma [Phase 3]

View source ↗

Summary

Phase 3 trial investigating vemurafenib plus cobimetinib in advanced BRAFV600-mutant melanoma has been withdrawn.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Melanoma

Drugs mentioned

• Cotellic (cobimetinib)
• Zelboraf (vemurafenib)

Snippet

Sponsor: Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins | Conditions: Melanoma | Phase 3 | Status: WITHDRAWN